Ozempic and Zepbound Hair Loss in Women: What's Causing It and What Helps

Yes, these medicines can be followed by hair loss, and women report it far more than men. On Zepbound, 7.1% of women reported hair loss against 0.5% of men. On Wegovy, the weight-loss brand of semaglutide (the medicine in Ozempic), it was 4% against 0.9%⁷⁸. The labels link it to weight loss, and it usually grows back.

Shedding on a GLP-1 is rarely just one thing

Search "does GLP-1 cause hair loss" and every answer says the same sentence: it is telogen effluvium, it is triggered by rapid weight loss rather than the drug itself, and it grows back. That is broadly right¹² — and for a lot of women it is also incomplete in a way that costs months.

The reason is that the years when women are most likely to start a GLP-1 are the same years when two other things start thinning hair: the perimenopausal hormonal transition⁴, and androgen- or iron-driven thinning that was already underway quietly. A GLP-1 does not switch those off. It adds a shed on top of them. So the honest question is not "is my hair loss from the medication" — it is "how much of it is, and what is the rest." This is general education, not a diagnosis; hair loss is one of the things worth taking to a clinician rather than a search bar.

How common is hair loss on Ozempic, Wegovy and Zepbound?

The weight-loss labels report hair loss by sex, and the gap is large.

Sources: the Zepbound, Wegovy and Foundayo prescribing information⁷⁸⁹. Each label says the hair loss was associated with weight reduction, and in the Zepbound trials no one on the drug stopped treatment because of it⁷.

Ozempic itself is approved for type 2 diabetes at doses up to 2 mg a week, and its label gives no trial rate for hair loss. It lists alopecia among side effects reported after approval, where the true frequency can't be measured¹⁰. Because Ozempic and Wegovy contain the same medicine, the Wegovy figures are the closest guide for a woman using semaglutide to lose weight.

What medication-linked shedding actually looks like

Telogen effluvium is a synchronizing event. A metabolic stressor — rapid weight loss, a lower calorie intake, less protein than the body was used to — pushes an unusually large share of follicles out of the growth phase at the same time, and they let go together a couple of months later¹². Its signature is specific:

• It is diffuse. The whole scalp thins at once. It does not carve out a part line or a hairline.
• It is a shed, not a thinning. Hair comes out — in the shower, in the brush, in handfuls — with a small white bulb at the root.
• It is late. It starts roughly two to four months after the weight loss got fast, which is why so many women blame the wrong month's dose change.
• It is self-limiting. The follicle is not damaged. Shedding slows once weight loss slows, and density rebuilds over months.

If that is the whole picture, the treatment is mostly patience plus removing the amplifiers — enough protein, enough total calories, and a rate of weight loss that is not outrunning what the rest of the body can support. Not all GLP-1 users shed, and the rate of loss matters more than which molecule you are on².

What perimenopausal thinning looks like instead

This one is not a shed, and it is the one most often misfiled as "the medication."

Through the menopause transition, falling estrogen shifts the balance of hormonal signaling at the follicle, and hair moves toward a female-pattern distribution: the part line widens, the crown loses density, the hairline holds⁴. It is gradual rather than dramatic. There is no handful in the shower. And unlike telogen effluvium it does not resolve on its own when weight stabilizes — waiting it out is precisely the wrong move, because female-pattern loss responds best when it is treated early.

The practical tell: a shed that ends is telogen effluvium; a part that keeps widening is not. If density is still falling six to nine months after weight loss leveled off, the GLP-1 has stopped being a sufficient explanation.

Hair is not the only thing that changes in these years; menopause belly is the other change women most often blame on the medication.

When androgens are the driver

For women with PCOS, elevated androgens can drive scalp thinning in the same female-pattern distribution, and it often predates the GLP-1 by years⁶. Weight loss can improve the underlying metabolic picture, but the thinning has its own trajectory and its own treatments. If your hair was already thinning at the crown before you started, the medication is not the story — see our PCOS guide for how that conversation should go.

The two labs that settle most of it

This is the part that gets skipped, and it is the cheapest information available.

Ferritin. Iron deficiency is meaningfully associated with non-scarring hair loss in women³, and the women most likely to be low are exactly the ones on a GLP-1 in midlife: heavy or irregular perimenopausal bleeding on one side, sharply reduced food intake on the other. Ferritin can be low enough to affect hair while a standard hemoglobin looks entirely normal — so "my blood count was fine" does not rule it out.

Thyroid. Thyroid dysfunction is a standard part of the hair-loss differential and is several times more common in women⁵ — and if you're already on levothyroxine, a GLP-1 can plausibly shift how much of it you absorb, which our guide to GLP-1 and thyroid conditions covers in more depth than a shedding checklist alone can.

Both are ordinary blood tests. A provider that reflexively runs them when a patient reports shedding is doing the job; one that says "that's normal, it passes" without looking is guessing. Our labs and monitoring guide covers what a thorough panel includes and what to ask for by name.

What actually changes the outcome

• Protein and total intake. Appetite suppression is the point of the medicine, which makes under-eating protein the easiest mistake to make on it. This is the single most modifiable amplifier — and if under-eating goes further than an amplifier, our guide to GLP-1 and eating disorder history covers when restriction itself needs its own conversation with a clinician.
• The rate of loss. Very fast loss is the trigger¹². Slowing the pace — including via dose — is a real conversation to have with a prescriber rather than a failure.
• Testing rather than assuming. Ferritin and thyroid, before spending months on supplements aimed at the wrong cause.
• Time, honestly counted. Regrowth is measured in months, and new growth arrives as short baby hairs along the part before length returns.

What does not help: guessing which cause it is from a photo, or switching molecules on the assumption that another GLP-1 will not do it.

What this means for choosing care

A shed is where the quality of the care around the prescription becomes visible. The question worth asking a program before you need the answer is whether it will actually run labs and adjust — or whether the only lever it has is the next dose. Our Luna Fit Score methodology explains how we weight clinical oversight, and how each program scores for women shows where that lands. If you are moving through the menopause transition, our guide to GLP-1 care through the perimenopause transition covers the wider picture this sits inside, and shedding is not the only thing rapid loss costs — lean mass goes too, on a timeline that matters more after 45.

Shedding is one item on a longer list; our hub on GLP-1 side effects in women covers the rest.